{"entity":{"id":"nct07249905","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma","aka":[],"tldr":"A phase 1/2 trial of MDX2003 in non-Hodgkin lymphoma, waldenström macroglobulinaemia, diffuse large B-cell lymphoma and follicular lymphoma, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.","summary":"Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma is a phase 1/2 interventional study registered as NCT07249905 by ModeX Therapeutics, An OPKO Health Company, with 180 participants planned, started 2026-04-13 and due to reach its primary completion in 2028-01. Interventions recorded: MDX2003.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07249905","url":"https://clinicaltrials.gov/study/NCT07249905"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","waldenstrom","dlbcl","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07249905","phase":"1/2","setting":"A Phase 1/2 Clinical Study Evaluating MDX2003 in Participants With Relapsed, Progressive, or Refractory B-Cell Malignancies","sponsor":"ModeX Therapeutics, An OPKO Health Company","enrolled":180,"outcomes":[]},"route":"/trials/nct07249905/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}]}}